Canady Life Sciences Acquires French Robotic Surgical Company Endocontrol and its Voice-Operated Robotic Technology

TAKOMA PARK, Md.--(BUSINESS WIRE)-- Canady Life Sciences, Inc. (A Delaware Corporation) announced today the acquisition of the French robotic company, Endocontrol (La Tronche, France). Canady Life Sciences (CLS) is a life sciences company that will consolidate US Medical Innovations, LLC and US Patent Innovations, LLC (Takoma Park, Md.) under its corporate umbrella in order to integrate and grow its business and products.

Endocontrol (http://www.endocontrol-medical.com/en/home/) was founded in 2006 and designs, manufactures and markets robotic assisted solutions for mini-invasive and laparoscopic surgery. The company offers a motorized robotic endoscopic positioner for laparoscopy via voice or foot control, and an ultra-compact motorized uterus positioner for gynecologic surgery (VIKY system). In addition, Endocontrol has developed a 5mm motorized articulated surgery instrument that gives access to intra-abdominal areas (JAIMY System), and a robotic needle holder. The Endocontrol robotic technology is protected by 10 patents and various trademarks. The company has sold over 200 robots worldwide.

The VIKY M is used in Gynecological, Urological and General Laparoscopic Surgery. VIKY XS is used in Pediatric, Thoracic and Laparoscopic Surgery. VIKY X, with a larger diameter is used in single-port and single-incision laparoscopic surgery.

The JAIMY Robotic Needle Holder 5mm has been used in Colorectal Surgery, Partial Nephrectomy, Radical Prostatectomy, Gastrectomy, Esophagectomy and Bariatric Bypass Surgery.

The VIKY System is FDA and CE Mark approved. The JAIMY is CE Mark approved. The robotic systems have been sold in 15 countries worldwide (USA, Europe, Southeast, Asia, Latin America, and the Middle East).

Clement Vidal (CEO and co-founder) will remain the CEO at Endocontrol. Mr. Vidal received his engineering degree from France’s Ecole Polytechnique and his master’s degree in mechanical engineering from Stanford University.

Dr. Jerome Canady (CEO, USMI and Chairman of USPI’s family of companies) commented, “The Endocontrol acquisition will accelerate USMI’s entrance into the robotic surgical market. This acquisition will increase our Intellectual Patent Portfolio to over 195 patents and filings globally. This voice-operated technology will be used with Canady Robotic Optical Navigation System (CRONS). CRONS will deliver our Cold Plasma Energy Beam technology for ablation of cancer at the surgical site without the use of the human hand. The Endocontrol products will be sold with the Canady SR-70 Robotic^TM System for free-standing and hospital-based ambulatory surgical centers and hospitals. The Canady/Endocontrol robotic instrument will allow the surgeon to perform robotic-assisted Laparoscopic, Thoracoscopic and Mini-invasive Surgery at the operating room table instead of working from a modular work station placed away from the patient. Our new robotic technology will provide voice-operated controls, advanced ergonomics, haptic feedback with SMART and 4K technology. The USMI robotic-assisted system will be priced up to 70% less than the current robotic-assisted surgical systems on the market. The VIKY and JAIMY are also reusable. We plan to launch our Canady/Endocontrol Robotic Assisted Surgical System in the 4^th quarter 2019.”

About Us

US Medical Innovations, LLC based out of Takoma Park, MD, is a privately-held FDA registered life science, biomedical and robotic device company. USMI is dedicated to expanding the boundaries of plasma medicine by pioneering new technologies for the development of state-of-the-art medical devices that advance patient outcomes and improve human lives.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190612005467/en/